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on heart rate variability in uncontrolled
hypertensive patients with chronic
kidney diseaseRecently, we observed that patients with CKD stage 4 seem to be
more susceptible to ventricular arrhythmias than patients without
CKD, due to a larger absence of voltage, in the left ventricular walls of
the ﬁrst ones [1]. In agreement with previous studies, Carreira and col-
leagues [2] reported that heart rate variability (HRV) in the 24-h Holter
was lower in patients with end stage of renal disease (ESRD) denoting
impaired autonomic function [3–7]. Kidney disease induces cardiac re-
modeling including left ventricular hypertrophy (LVH) and heart ﬁbro-
sis. Several clinical studies, including those who recruited participants
with mild-to-moderate reduction in estimated glomerular ﬁltration
rate (eGFR), showed an independent association between CKD and
LVH [8–11]. Speciﬁcally, there is a progressive increase in the preva-
lence of LVH, and left ventricular mass increased when the eGFR de-
creases. In addition, among participants with more advanced kidney
disease on dialysis, magnetic resonance imaging (MRI) with contrast
demonstrates a diffuse pattern image with gadolinium uptake sugges-
tive of ﬁbrosis and non-ischemic cardiomyopathy [12]. These structural
changes in cardiac conduction delay ventricular activation and create
late potentials in the terminal portion of theQRS complex. Furthermore,
these low amplitude signals, which may be detected using a high-
resolution electrocardiogram, were identiﬁed in 25% of patients on dial-
ysis [13]. According to Brotman and colleagues in their study, time and
frequency domain measures were similarly and signiﬁcantly associated
with ESRD and CKD-related hospitalizations, suggesting that autonomic
dysfunction may be an important risk factor for ESRD and CKD-related
hospitalizations [14].
Sympathetic hyperactivity is well known to increase cardiovascular
risk in CKD patients and is a hallmark of an essential hypertensive
state that occurs early in the clinical course of the disease [15–17]. In
both conditions, hypertension and kidney failure, the mechanisms of
hyperadrenergic state are varied and include reﬂex and neurohumoral
pathways [15,16,18]. In CKD, the sympathetic hyperactivity seems to
be expressed at the earliest clinical stage of the disease, showing a direct
relationship with the severity of the condition of renal impairment [18–
21]. The increased sympathetic tone alters renal function because of the
retention volume of sodium reabsorption, a decrease in renal blood
ﬂow, and activation of the renin-angiotensin-aldosterone system [22].
Meta-analyses have shown that impaired renal function is an indepen-
dent cardiovascular risk factor [23], and other studies reported that ad-
renergic activation exhibits an adverse impact on cardiovascular
morbidity and, in the case of kidney failure, also on cardiovascularmor-
tality [15,16,21,24]. Consequently, prevention of further damage to
renal function is a therapeutic target by itself [25]. A strategy using per-
cutaneous catheter-based delivery of radiofrequency (RF) energy was
recently settled to interject the sympathetic innervation of the kidneys.http://dx.doi.org/10.1016/j.ijcme.2016.11.010
2214-7624/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access articlThis new procedure exposed no severe vascular or renal complications
in the long term (up to 36 months). Our group believes that uncon-
trolled hypertensive patients with CKD can be beneﬁted from the
renal sympathetic denervation (RSD), regarding amelioration of the
eGFR and HRV.
This prospective longitudinal study involved 24 patients with CKD
stage 4 and uncontrolled hypertension. The study was conducted in
agreementwith theHelsinki declaration and approved by the ethics com-
mittee of our institution. All patients signed the informed consent term
before inclusion. This study was conducted at the Hospital e Clínica São
Gonçalo, Rio de Janeiro, Brazil. Patients were recruited from January
2015 till January 2016 from the Cardiology Service of the same hospital.
Enrolled patients met the following criteria: (i) a heart with an ejection
fraction of N50% as measured by echocardiography (Simpson's method),
(ii) aged 18 to 80 years, (iii) patientswith CKD stage 4: estimated glomer-
ular ﬁltration rate (eGFR) between 15 and 29mL/min/1.73m2, calculated
using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation [26], (iv) mean 24-hour ABPM ≥130/≥80 mm Hg despite treat-
ment with non-pharmacological measures and use of at least three anti-
hypertensive drugs (including a diuretic) on maximally tolerated doses
or conﬁrmed intolerance to medications; (v) hypertensive essential
state documented at least more than one year, and (vi) the capacity to
read, comprehend and sign the informed consent form, and attend the
study. Patients with any of the following were excluded: (i) pregnancy;
(ii) valvular disease with signiﬁcant adverse sequelae; (iii) unstable angi-
na, myocardial infarction, transient ischemic attack or stroke previously;
(iv) psychiatric disease; (v) the inability to be monitored clinically after
the procedure; (vi) a known addiction to alcohol or drugs that affects
the intellect; (vii) congestive heart failure (symptoms of functional class
II to IV heart failure on the New York Heart Association scale).
The subjects were divided into two groups according to the proce-
dure performed: control group (n = 13) and RSD group (n = 11). Pa-
tients underwent a 24 h-Holter (Galix Biomedical Instrumentation,
Florida, USA). A 3-channel recorderwas used to record the electrocardio-
graphic traces. A time domain analysis of HRV was performed, and the
following parameters were obtained: a) SDNN, standard deviation (SD)
of all normal RR intervals (NN); b) SDANN, SD of the averages of 5-min
NN intervals over 24-h; c) rMSSD, the square root of the mean of the
square of successive NN intervals; and d) triangular index (TI), integral
of the density distribution (that is, the number of all NN intervals) divid-
ed by the maximum density distribution. Cutoff values adopted in the
present study were derived from a previous study in which SDNN
b50 ms, SDANN b40 ms, rMSSD b15 ms, and TI b15 were deﬁnitely as-
sociatedwith increased cardiovascular mortality in CKD patients [5]. The
24-hour ABPM [27] and the RSD procedure [28] has been described in
detail previously. The patients remained hospitalized in the ward for
24 h after the procedure.
The results are expressed as a mean and standard deviation for nor-
mally distributed data and as median with interquartile range other-
wise. Comparisons between two-paired values were performed with
the paired t-test in cases of a Gaussian distribution and by theWilcoxone under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
General features of patients at baseline.
Parameters Control group RSD group Overall P value
N 13 11 –
Age, years 62.3 ± 12.5 59.7 ± 9.3 0.5753
Body mass index, kg/m2 26.5 ± 3.2 27.1 ± 3.9 0.6827
Male gender (%) 9 (69%) 7 (64%) N0.9999
White ethnicity (%) 8 (62%) 8 (73%) 0.6792
Uncontrolled hypertension 13 (100%) 11 (100%) 1.0000
Coronary artery disease 4 (31%) 4 (36%) N0.9999
Type 2 diabetes mellitus 6 (46%) 6 (55%) N0.9999
Creatinine, mg/dL 2.70 ± 0.21 2.80 ± 0.15 0.6643
CKD stage 4 13 (100%) 11 (100%) 1.0000
eGFR, mL/min/1.73 m2 24.0 ± 4.7 23.3 ± 3.1 0.9729
Albumin:creatinine ratio, mg/g 96.5 ± 22.1 90.2 ± 25.8 0.9281
Antihypertensive
ACE-inhibitors/ARB 13 (100%) 11 (100%) 1.0000
Diuretics 13 (100%) 11 (100%) 1.0000
DHP Ca++ channel blockers 13 (100%) 11 (100%) 1.0000
α-2 adrenergic agonist 9 (69%) 7 (64%) N0.9999
Mean 24-hour systolic/diastolic ABPM, mmHg 134.9 ± 78.5/84.2 ± 6.6 136.5
± 9.0/85.8 ± 8.5
0.9602/0.9222
24-hour-Holter monitoring
SDNN, ms 32.5 ± 4.4 31.6 ± 7.1 0.9909
SDANN, ms 26.0 ± 2.1 28.9 ± 5.0 0.4942
rMSSD, ms 8.2 ± 1.7 8.0 ± 1.5 0.9906
TI 8.4 ± 2.7 8.5 ± 2.6 N0.9999
Values are expressed asmean±SD;ABPM, ambulatory blood pressuremeasurements; ACE, angiotensin-converting enzyme;AF, atrialﬁbrillation; ARB, angiotensin receptor blocker; CKD,
chronic kidney disease; DHP, dihydropyridine; eGFR, estimated glomerular ﬁltration rate; rMSSD, the square root of the mean of the square of successive NN intervals; SDANN, SD of the
averages of 5-minNN intervals over 24-h; SDNN, standard deviation (SD) of all normal RR intervals (NN); and triangular index (TI), integral of the density distribution (that is, the number
of all NN intervals) divided by the maximum density distribution.
30 Correspondencetest otherwise. For normality of distribution, D'Agostino-Pearson test
was used. Comparisons between more than two-paired values were
made by repeated-measures analysis of variance or by Kruskal–Wallis
analysis of variance as appropriate, complemented by the post-hoc
Tukey test. Categorical variables were compared with Fisher's exact
test. A two-tailed P-value b 0.05was used as a criterion for statistical sig-
niﬁcance. All statistical analyses were performed using the program
Graphpad Prism v 7.0 (Graphpad Software, La Jolla, CA, USA).
The general features of the two groups of patients are listed in
Table 1. The comparisons between the control and the RSD group, re-
garding mean 24-hour ABPM and renal function are displayed in
Table 2. The parameters that determine the HVR recorded by the
24-hour-Holter monitoring as: SDNN (Fig. 1A), SDANN (Fig. 1B),
rMSSD (Fig. 1C) and TI (Fig. 1D), from the control subjects at baseline
vs. the 6th month of follow-up were 32.5 ± 4.4 vs. 33.1 ± 3.2 msTable 2
Variation (Δ) of mean systolic/diastolic 24-hour ABPM and renal function at baseline vs. 6th m







Δ of mean systolic 24-hour
ABPM, mmHg
+1.6 ± 3.2 +1.8 ± 3.1
Δ of mean diastolic 24-hour
ABPM, mmHg
+1.6 ± 2.5 +1.6 ± 2.4
Control (n = 13)
at baseline
RSD (n = 11)
at baseline
Creatinine, mg/dL 2.70 ± 0.21 2.80 ± 0.15
eGFR, mL/min/1.73 m2 24.0 ± 4.7 23.3 ± 3.1
Albumin:creatinine ratio, mg/g 95.5 ± 22.1 90.2 ± 25.8
Values are presented as mean ± SD; ABPM, ambulatory blood pressure measurements; eGFR,(P = 0.9938), 26.0 ± 2.1 vs. 26.2 ± 4.3 ms (P = 0.9998), 8.2 ± 1.7
vs. 8.3 ± 1.4 ms (P = 0.9996), and 8.4 ± 2.7 vs. 10 ± 2.8 (P =
0.4789), respectively. In the RSD group the comparisons for the
same sequence of parameters at baseline vs. the 6th month of
follow-up were 31.6 ± 7.1 vs. 56.7 ± 10.9 ms (P b 0.0001), 28.9 ±
5.0 vs. 41.6 ± 7.6 ms (P b 0.0001), 8.0 ± 1.5 vs. 16.9 ± 2.7 ms
(P b 0.0001), and 8.5 ± 2.6 vs. 16.1 ± 3.2 (P b 0.0001), respectively.
Comparing the both groups at the 6th month of follow-up we en-
countered a variation (Δ) of 23.6 ± 2.8 ms for SDNN, 15.5 ± 2.1 ms
for SDANN, 8.6 ± 0.8 ms for rMSSD, and 6.2 ± 1.1 for TI (P b 0.0001
for all the comparisons).
So, we can conclude that there was a signiﬁcant reduction on 24-
hour ABPM, and an improvement of renal function and HRV, in patients
underwent RSD. Randomized trials with a greater number of subjects
are necessary.onth of follow-up.













−14.7 ± 3.4 −14.9 ± 3.2 0.0004 0.0002
−11.4 ± 2.6 −11.4 ± 2.5 0.0005 0.0003
Control (n = 13)
at 6th month









2.80 ± 0.20 2.40 ± 0.30 0.0004 0.0002
23.0 ± 3.0 28.3 ± 5.0 0.0248 0.0111
100.1 ± 30.8 46.3 ± 20.0 0.0010 b0.0001
estimated glomerular ﬁltration rate; RSD, renal sympathetic denervation.
Fig. 1. The SDNN (A), SDANN (B), rMSSD (C) and TI (D) in control patients (n= 13) vs. patients underwent RSD (n= 11); CKD, chronic kidney disease; SDNN, standard deviation (SD) of
all normal RR intervals (NN); SDANN, SD of the averages of 5-minNN intervals over 24-h; rMSSD, the square root of themean of the square of successiveNN intervals; and triangular index
(TI), integral of the density distribution (that is, the number of all NN intervals) divided by the maximum density distribution.
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